Suppl. table 1. Clinical characteristics in patients with low and high Ed/Ea before discharge and 1 year after discharge: cutoff point of Ed/Ea for all-cause mortality

	Ed/Ea: Before discharge		*p-value (low vs. high)*	Ed/Ea: 1 Year after		*p-value (low vs. high)*
	low (≤ 0.132)	high (>0.132)		low (≤ 0.132)	high (>0.132)	
	n = 398	n = 261		n = 229	n = 115	
All-cause mortality, n (%)	26 (7)	45 (17)	*<0.001*	10 (4)	14 (12)	*0.007*
Age, years	80 ± 9	83 ± 9	*0.001*	80 ± 9	83 ± 7	*0.001*
Male sex, n (%)	204 (51)	92 (35)	*<0.001*	110 (48)	47 (41)	*0.126*
Systolic blood pressure, mmHg	122 ± 19	120 ± 19	*0.238*	132 ± 21	128 ± 22	*0.082*
Diastolic blood pressure, mmHg	66 ± 12	64 ± 11	*0.017*	70 ± 13	65 ± 11	*0.003*
Heart rate, bpm	70 ± 15	70 ± 15	*0.731*	70 ± 15	68 ± 13	*0.157*
Atrial fibrillation, n (%)	178 (45)	112 (43)	*0.646*	106 (46)	46 (40)	*0.160*
Coronary artery disease, n (%)	64 (16)	58 (22)	*0.029*	32 (14)	31 (27)	*0.002*
Diabetes mellitus, n (%)	134 (34)	99 (38)	*0.150*	81 (35)	45 (39)	*0.286*
Dyslipidemia, n (%)	155 (39)	115 (44)	*0.110*	97 (42)	59 (51)	*0.072*

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Hypertension, n (%)	330 (83)	235 (90)	*0.007*	199 (87)	101 (88)	*0.471*
Laboratory data						
Albumin, g/dL	3.4 ± 0.5	3.4 ± 0.5	*0.934*	3.9 ± 0.4	3.8 ± 0.5	*0.022*
eGFR, mL/min/1.73 m^2	45 ± 19	41 ± 19	*0.009*	44 ± 19	35 ± 18	*<0.001*
Hemoglobin, g/dL	11.5 ± 2.0	11.2 ± 2.0	*0.057*	12.0 ± 1.7	11.5 ± 1.9	*0.007*
NT-proBNP, pg/mL	1957 ± 3634	3483 ± 8136	*0.001*	1755 ± 2921	4608 ± 8051	*<0.001*
Echocardiographic data						
LAD, mm	43 ± 9	45 ± 8	*0.004*	44 ± 9	46 ± 7	*0.033*
LAVI, mL/m^2	52 ± 25	56 ± 24	*0.045*	53 ± 27	55 ± 20	*0.598*
SV/LAV	0.74 ± 0.36	0.66 ± 0.33	*0.015*	0.72 ± 0.33	0.63 ± 0.31	*0.038*
SV, mL	50 ± 19	50 ± 21	*0.999*	50 ± 18	47 ± 18	*0.275*
LVESV, mL	34 ± 18	32 ± 17	*0.091*	33 ± 17	29 ± 12	*0.011*
LVEDV, mL	83 ± 34	81 ± 35	*0.385*	83 ± 30	76 ± 28	*0.043*
LVEF, %	60 ± 8	61 ± 8	*0.105*	62 ± 8	62 ± 9	*0.906*
LVMI, g/m^2	104 ± 32	110 ± 36	*0.017*	99 ± 31	107 ± 31	*0.013*
E, m/sec	0.72 ± 0.22	1.02 ± 0.31	*<0.001*	0.75 ± 0.24	1.01 ± 0.31	*<0.001*
mean e', cm/sec	7.1 ± 2.1	5.5 ± 1.7	*<0.001*	6.8 ± 2.2	6.0 ± 1.9	*<0.001*
DcT, sec	0.21 ± 0.06	0.23 ± 0.08	*0.002*	0.21 ± 0.06	0.22 ± 0.09	*0.378*
Medications						
Beta-blockers, %	52	58	*0.131*	50	59	*0.104*

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Calcium-channel blockers, %	**50**	**54**	*0.296*	**47**	**54**	*0.218*
Diuretics, %	**81**	**86**	*0.138*	**77**	**85**	*0.083*
RAAS-I, %	**73**	**75**	*0.413*	**71**	**67**	*0.391*
Statins, %	**31**	**35**	*0.258*	**34**	**39**	*0.318*

All-cause mortality was evaluated for 2 years per year.

Values are mean ± standard deviation or number (%).

DcT, deceleration time of E wave;

Ed, diastolic elastance; Ea, arterial elastance; eGFR, estimated glomerular filtration rate;

NT-proBNP, N-terminal pro-brain natriuretic peptide; LAD, left atrial diameter;

LAVI, left atrial volume index; SV, stroke volume; LAV, left atrial volume;

LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume;

LVEDV, left ventricular end-diastolic volume; LVMI, left ventricular mass index;

RAAS-I, renin-angiotensin-aldosterone system inhibitors